Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | miconazole | 2805 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | miconazole | 2805 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | miconazole | 2805 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | miconazole | 2805 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | miconazole | 2805 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | miconazole | 2805 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | miconazole | 2805 | drug-path |
| B cell receptor signaling pathway | R-HSA-983705 | map04662 | oxybuprocaine | 4633 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | oxybuprocaine | 4633 | drug-path |
| Fc epsilon RI signaling pathway | R-HSA-2454202 | map04664 | oxybuprocaine | 4633 | drug-path |
| VEGF signaling pathway | R-HSA-194138 | map04370 | oxybuprocaine | 4633 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | oxybuprocaine | 4633 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | oxybuprocaine | 4633 | drug-path |
| Long-term depression | R-HSA-9620244 | map04730 | oxybuprocaine | 4633 | drug-path |
| Renal cell carcinoma | R-HSA-9794523 | map05211 | oxybuprocaine | 4633 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | oxybuprocaine | 4633 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | oxybuprocaine | 4633 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | oxybuprocaine | 4633 | drug-path |
| Epithelial cell signaling in Helicobacter pylori infection | 0 | map05120 | oxybuprocaine | 4633 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | oxybuprocaine | 4633 | drug-path |